VOLUNTARY ANNOUNCEMENT ACHIEVEMENT OF THE PRIMARY ENDPOINT IN PHASE III CLINICAL TRIAL OF RECOMBINANT ANTI-HUMAN IL-17A/F HUMANIZED MONOCLONAL ANTIBODY INJECTION
POLL RESULTS OF THE ANNUAL GENERAL MEETING FOR THE YEAR 2024,THE 2025 FIRST CLASS MEETING OF A SHAREHOLDERS AND THE 2025 FIRST CLASS MEETING OF H SHAREHOLDERS HELD ON 29 MAY 2025